

IPDF SHORT DAPT STRATEGY IN THE CONTEMPORARY PCI ERA: ...
www.summitmd.com/pdf/pdf/8167.pdf

EVOLVE Short DAPT Co-Primary Endpoint: Adjusted Death/MI between 3-15 months with 3-Month DAPT Compared to Historical Control 5.7 5.6 0.5 10 12-month DAPT 3-month DAPT 3-% N=1493 N=1454-5 0.5 Difference [97.5% UCB] P=0.0016 Non-inferiority margin: 2.52% 1.63% 1-sided UCB* Patients with respective event or sufficient follow-up included in the denominator

Dual Antiplatelet Therapy After Percutaneous Coronary ...

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046308

Cited by: 15 Author: Safi U. Khan, Maninder Singh, Shahul Valavoor, M...

Publish Year: 2020

The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) remains unsettled. 1 In patients with chronic coronary syndrome, the 2016 American College of Cardiology/American Heart Association update recommended DAPT (aspirin and a P2Y12 inhibitor) for 6 months after PCI with drug-eluting stent (DES), with the potential to extend DAPT for a longer duration in those who remain free of a bleeding complication during this period ...

Search Tools

Turn on Hover Translation (开启敬词)

PEOPLE ALSO ASK

What are the benefits of DAPT after PCI?

What is The difference between short term DAPT and 12 month DAPT?

Dual antiplatelet therapy and non-cardiac surgery ...

<https://pubmed.ncbi.nlm.nih.gov/28184261>

Dual antiplatelet therapy (DAPT) consisting of aspirin plus a P2Y₁₂ inhibitor (clopidogrel, prasugrel, or ticagrelor) is imperative for the treatment of acute coronary syndrome, particularly during the re-endothelialization period after percutaneous coronary intervention (PCI). When patients undergo surgery during this period, the consequences of stent thrombosis are far more serious than ...

Cited by: 10 Author: Jong Wook Song, Sarah Soh, Jae-Kwang...

Publish Year: 2017



[Short dual antiplatelet therapy: how, when and why]

<https://pubmed.ncbi.nlm.nih.gov/32134404>

Dual antiplatelet therapy (DAPT) is a cornerstone of antithrombotic treatment in patients undergoing

Name of Journal: World Journal of Cardiology
Manuscript Type: REVIEW
Shortened DAPT in contemporary PCI era
Jennie Han, BM BCh, Department of Cardiology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Nadeem Attar, MD, MRCP(UK), Department of Cardiology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Author contributions: Jennie Han and Nadeem Attar wrote the paper
Correspondence to: jenniehan95@gmail.com, ORCID: 0000-0002-7089-8923
nadattar@hotmail.com, ORCID:0000-0002-7087-6441

Match Overview		
1	Internet 56 words repub-eur.nl	1%
2	Internet 47 words crawled on 19-Nov-2020 academic.oup.com	1%
3	Internet 44 words crawled on 10-Jul-2020 www.jstage.jst.go.jp	1%
4	Crossref 31 words "Textbook of Catheter-Based Cardiovascular Interventions", Springer Science and Business Media LLC, 2019	1%
5	Internet 31 words crawled on 28-Feb-2021 www.tnq.com	1%
6	Internet 24 words crawled on 25-Mar-2021 www.medicvamedica.it	1%

国内版

国际版

Shortened dual antiplatelet therapy in contemporary percutaneous



ALL

IMAGES

VIDEOS

39,100 Results

Any time ▾

Very short dual antiplatelet therapy after PCI and new DES ...

<https://pubmed.ncbi.nlm.nih.gov/32482558>

Introduction and objectives: Very early (1-3 months) discontinuation of **dual antiplatelet therapy (DAPT)** has been recently proposed in **percutaneous coronary interventions** with **modern drug-eluting stents (DES)**, with contrasting results. The aim of the present meta-analysis was to evaluate the prognostic impact of **very short DAPT** regimens vs the standard 12-month regimen in patients undergoing **percutaneous coronary intervention** ...

Author: Monica Verdoia, Elvin Khedi, Harry Su... Publish Year: 2021

Dual antiplatelet therapy and non-cardiac surgery ...

<https://pubmed.ncbi.nlm.nih.gov/28184261>

Dual antiplatelet therapy (DAPT) consisting of aspirin plus a P2Y₁₂ inhibitor (clopidogrel, prasugrel, or ticagrelor) is imperative for the treatment of acute **coronary syndrome**, particularly during the re-endothelialization period after **percutaneous coronary intervention (PCI)**. When patients undergo surgery during this period, the consequences of stent thrombosis are far more serious than ...

Cited by: 10 Author: Jong Wook Song, Sarah Soh, Jae-Kwang...
Publish Year: 2017

Monotherapy With Prasugrel After Dual-Antiplatelet Therapy ...

<https://pubmed.ncbi.nlm.nih.gov/33162490>

Background: The risks of bleeding and cardiovascular events in high bleeding risk (HBR) Japanese patients undergoing **percutaneous coronary intervention (PCI)** while receiving single-**antiplatelet therapy (SAPT)** remains unknown. We aimed to evaluate the frequency of bleeding and cardiovascular events associated with prasugrel monotherapy after **short-term dual-antiplatelet therapy (DAPT)** in ...

Cited by: 5 Author: Masato Nakamura, Yoshihiro Morino, Tsu...
Publish Year: 2020

Dual Antiplatelet Therapy in Percutaneous Coronary ...

<https://www.ahajournals.org/doi/full/10.1161/circinterventions.116.003587>

Feb 08, 2016 · Stephan Windecker From the Department of Cardiology, Bern University Hospital, Bern, Switzerland. In 2016, **dual antiplatelet therapy (DAPT)** assumes its 20th anniversary since the publication of the first randomized clinical trial establishing the superiority of DAPT over anticoagulant therapy among patients undergoing **percutaneous coronary intervention (PCI)** (Figure). 1 Because